A R T I C L E I N F O
Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide 
A B S T R A C T
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder that is closely associated with insulin resistance and type 2 diabetes. Previous studies have suggested that hepatocyte nuclear factor 1b (HNF1b) ameliorates insulin resistance. However, the role of HNF1b in the regulation of lipid metabolism and hepatic steatosis remains poorly understood. We found that HNF1b expression was decreased in steatotic livers. We injected mice with lentivirus (LV) expressing HNF1b shRNA to generate mice with hepatic knockdown of HNF1b. We also injected high fat (HF) diet-induced obese and db/db diabetic mice with LV expressing HNF1b to overexpress HNF1b. Knockdown of HNF1b increased hepatic lipid contents and induced insulin resistance in mice and in hepatocytes. Knockdown of HNF1b worsened HF diet-induced increases in hepatic lipid contents, liver injury and insulin resistance in mice and PA-induced lipid accumulation and impaired insulin signaling in hepatocytes. Moreover, overexpression of HNF1b alleviated HF diet-induced increases in hepatic lipid content and insulin resistance in mice. Knockdown of HNF1b increased expression of genes associated with lipogenensis and endoplasmic reticulum (ER) stress. DPP4 and NOX1 expression was increased by knockdown of HNF1b and HNF1b directly bound with the promoters of DPP4 and NOX1. Overexpression of DPP4 or NOX1 was associated with an increase in lipid droplets in hepatocytes and decreased expression of DPP4 or NOX1 suppressed the effects of knockdown of HNF1b knockdown on triglyceride (TG) formation and insulin signaling. Knockdown of HNF1b increased superoxide level and decreased glutathione content, which was inhibited by downregulation of DPP4 and NOX1. N-acetylcysteine (NAC) suppressed HNF1b knockdown-induced ER stress, TG formation and insulin resistance. Palmitic acid (PA) decreased HNF1b expression which was inhibited by NAC. Taken together, these studies demonstrate that HNF1b plays an essential role in controlling hepatic TG homeostasis and insulin sensitivity by regulating DPP4/NOX1mediated generation of superoxide.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide [1] . It is estimated that NAFLD accounts for up to 20% of the total population in the United States and 15% in China [2] . 10-15% of NAFLD patients have nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and hepatocellular carcinoma [3] . NAFLD is characterized by excessive fat accumulation in hepatocytes, mainly in the form of triglycerides (TGs) [4] . Uncontrolled lipogenesis contributes to development of NAFLD under several pathophysiological conditions, including diabetes, obesity, and insulin resistance [4] [5] [6] . Disorders of hepatic lipid metabolism are closely associated with NAFLD. However, the mechanisms underlying the pathogenesis of NAFLD are incompletely understood and effective preventive and therapeutic strategies are lacking.
Hepatocyte nuclear factor 1b (HNF1b), also named as vHNF1, HNF1β, TCF2 and LF-B3, is a member of the homeodomain-containing superfamily of liver-enriched transcription factors, which are highly conserved across species from yeast to human [7] . HNF1b recognizes the sequence 5′-GTTAATNATTAAC-3′ and mediates sequence-specific DNA binding through its POU-specific (Pit-1, OCT1/2, UNC-86; POUS) and atypical POU homeodomain (POUH) [8] . Truncated or loss-of-function HNF1b alleles cause maturity-onset diabetes of the young (MODY) 5, which is characterized by an early age of onset, usually at a mean age of 17-25.8 years (30-66%), genital malformations (12.0-62.5%), and an autosomal dominant mode of inheritance [9] [10] [11] [12] [13] . Some genome-wide association studies have shown that variants of HNF1b are associated with type 2 diabetes [14] [15] [16] [17] , while the opposite has been observed in different populations [18] . In addition, a large population-based cohort study demonstrates that genetic risk variants of HNF1b are significantly associated with lipoprotein traits, such as lipoprotein subclasses and particle composition [19] . In our previous study, we found that downregulation of HNF1b was involved in polychlorinated biphenyls (PCB)-153-induced oxidative stress and lipid accumulation in livers [20] . Overexpression of HNF1b increased GPx1 expression, decreased superoxide level, decreased sterol regulatory element-binding protein-1 (Srebp-1), fatty acid synthase (FAS) and acetyl CoA carboxylase expression, and inhibited PCB-153-resulted oxidative stress, NF-κB-mediated inflammation, and final glucose/lipid metabolic disorder [20] . However, the role of HNF1b in the regulation of lipid metabolism and hepatic steatosis remains poorly understood.
In order to elucidate the role of HNF1b in the pathogenesis of NAFLD and associated metabolic dysfunction, we injected mice with lentivirus (LV) expressing HNF1b shRNA to generate mice with liver knockdown of HNF1b. We also injected high fat (HF) diet-induced obese and db/db diabetic mice with LV expressing HNF1b to overexpress HNF1b. We observed that knockdown of HNF1b increased increase of hepatic lipid contents and induced insulin resistance in mice and in hepatocytes. In addition, knockdown of HNF1b worsened HF diet-induced increases in hepatic lipid content, liver injury and insulin resistance in mice and PA-induced lipid accumulation and disturbance of insulin signaling in hepatocytes. Moreover, overexpression of HNF1b alleviated HF diet-induced increases in hepatic lipid content and insulin resistance in mice. Our findings support the concept that HNF1b activators may have potential therapeutic benefit for the treatment of NAFLD.
Materials and methods

Animals and treatment
C57BL/6J mice were purchased from the Animal Center of Fourth Military Medical University. db/db mice were obtained from Model Animal Research Center of Nanjing University. For HF diet feeding, C57 mice were fed a chow diet or an HF diet (45% kcal from fat; Research Diets, New Bruns-wick, NJ) for 8 or 12 weeks. LVs expressing HNF1b or HNF1b shRNA were constructed commercially (Genechem, Shanghai, China). Each mouse was injected with 5 × 10 6 PFU LV through caudal vein in 500 μl phosphate buffered saline (PBS) twice in four weeks. 8-week old C57 mice were injected with LVs expressing HNF1b shRNA. C57 mice feeding with HF diet for 12 weeks and db/db diabetic mice were injected with LVs expressing HNF1b. C57 mice feeding with HF diet for 8 weeks were injected with LVs expressing HNF1b shRNA. For the detection of insulin signaling, mice were intraperitoneally injected with 10 U/kg insulin 30 min before euthanization. Unless otherwise stated, male mice were used and all mice were fasted for overnight before euthanization. All animal experiments were approved by the institutional animal care and use committee at Fourth Military Medical University.
Cell culture, treatment and transient transfection
AML-12 cells were purchased from the American Type Culture Collection (ATCC, USA). Cells were cultured in DMEM/F-12 medium containing 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO 2 atmosphere. Cells were transfected with LV expressing HNF1b shRNA and purified with puromycin to establish cell lines with stable knockdown of HNF1b. Transient transfection of pCMV-DPP4, pCMV-NOX1, shDPP4 or shNOX1 (GeneChem, Shanghai, China) was performed using Turbofect Transfection Reagents (Thermo Scientific, USA) according to the manufacturer's protocol. Cells were treated with 20 μM palmitic acid (PA) or oleic acid (OA) for 4 h to stimulate lipid accumulation. Cells were treated with 100 μM PA for 24 h to stimulate cellular insulin resistance.
Histology and lipid staining in tissues and cells
Liver tissues were fixed in 10% formalin and embedded in paraffin. Paraffin-embedded sections were stained with hematoxylin and eosin using a standard protocol. For lipid staining in tissues, frozen sections were prepared and stained with Oil Red O (Sigma, St. Louis, MO). For lipid staining in cells, cells were fixed in 10% paraformaldehyde and stained with Oil Red O or BODIPY 493/503 (Life Technologies, USA).
Biochemical determination
The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hepatic TG were measured using colorimetric assay kits (Nanjing Jiancheng, China).
Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT)
At the end of the experiment, IPGTT and IPITT were conducted to assess the metabolic activity in response to glucose or insulin load. Mice were fasted for 12 h, and basal level of blood glucose was measured using tail blood drops. Then, mice were intraperitoneally injected with D-glucose (Sigma, 1 g/kg), or insulin (Novolin Novolin R, 0.75 U/kg body weight, 0.75 U/kg body weight). Blood glucose level at 30, 60, and 120 min time points were measured using blood samples dropped from tails.
Glucose uptake
Glucose uptake was measured by a fluorescent glucose 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) method using a glucose uptake assay kit (Cayman Chemical, USA) according the manufacturer's protocols. Cells were incubated with 2-NBDG in the presence or absence of 100 nM insulin at 37°C for 30 min 2-NBDG content was determined using a microplate fluorimeter (Infinite M200; Tecan, Hillsborough, NC).
Real-time PCR and western blot
Real-time PCR and western blot were performed as we previously did [21] . For PCR, primers used were shown in Supporting Table S1 . Antibody dilution: β-actin: Santa Cruz, 1:500; HNF1b: Prosci Technology, 1: 1000; GRP78: Bioworld Technology, 1:500; CHOP: Bioworld Technology, 1:500; eIF2ɑ: Bioworld Technology, 1:500; P-eIF2ɑ: Santa Cruz, 1:500; PERK: Bioworld Technology, 1:500; P-PERK: Abcam, 1:1000; Akt: Cell Signaling Technology, 1:1000; P-Akt (S473): Cell Signaling Technology, 1:1000; PPARɑ: Santa Cruz, 1:500; PPARγ: Santa Cruz, 1:500; Srebp-1: Santa Cruz, 1:500; FAS: Cell Signaling Technology, 1:1000; FABP4: Cell Signaling Technology, 1:1000.
ChIP-PCR assay
HNF1b binding in the promoters of DPP4 and NOX1 was assessed by a ChIP assay using the Chromatin Immunoprecipitation Assay kit (Thermo Scientific, USA) according to the manufacturer's protocols. Subsequent PCR was conducted as detailed above. IgG binding was used as negative control.
Statistical analysis
Results were expressed as mean ± SEM. The statistical significance of differences between two groups was assessed by Student's t-tests. Differences between more than two groups were analyzed by one-way analysis of variance (ANOVA) followed by the Newmane Keuls multiple-comparison post hoc test using Graph-Pad Prism software. Data were considered to be statistically significant if p < 0.05.
Results
HNF1b expression is reduced in steatotic livers
To investigate whether HNF1b is associated with lipid accumulation in livers, we examined hepatic HNF1b expression in genetically obese db/db mice and HF diet-fed obese mice. As expected, db/db mice and HF diet-fed obese mice had severe liver steatosis (Supporting Fig. S1A and B). In both db/db mice (Fig. 1A, B ) and HF diet-fed mice (Fig. 1C,  D) , hepatic HNF1b messenger RNA (mRNA) level was reduced by greater than 50% (Fig. 1A , C) and HNF1b protein level was reduced by approximately 80% (Fig. 1B, D) . PA and OA induced a significant increase in lipid accumulation in AML-12 hepatocytes (Supporting Fig.  S1C and D). HNF1b mRNA level was markedly reduced by PA and OA treatment ( Fig. 1E and F) . We further analyzed the expression of HNF1b in fasting-induced fatty liver in mice. Here, decreased expression of HNF1b was also observed in the livers of mice after 24 h and 48 h fasting (Fig. 1G) . Together, the data indicate that HNF1b expression is reduced in steatotic livers, suggesting a role of HNF1b in the regulation of hepatic lipid metabolism.
Overexpression of HNF1b alleviates fatty liver and improves glucose tolerance
To determine whether HNF1b plays a role in hepatic lipid metabolism, we generated a lentivirus (LV) expressing HNF1b. db/db mice and HF diet-fed mice were injected with LV-HNF1b via tail vein. Overexpression of HNF1b was confirmed (Supporting Fig. S2A and B). Fasting blood glucose levels (Supporting Fig. S2E ), body weights (Supporting Fig. S2C , F), and liver weights (Supporting Fig. S2D , G) were not significantly altered except for the fasting blood glucose levels (Supporting Fig. S2B ) in db/db mice. HE and Oil Red O staining showed that hepatic lipid content was decreased in LV-HNF1b-injected db/db ( Fig. 2A) , HF diet-fed ( (Fig. 2J) . The data suggests that overexpression of HNF1b alleviates fatty liver and improves glucose tolerance in both genetic and diet-induced mice model of metabolic disorder.
HNF1b knockeddown exacerbated HF diet-induced fatty liver and glucose intolerance
To determine whether downregulation of HNF1b promotes HF dietinduced hepatic lipid accumulation, we generated a lentivirus (LV) expressing shHNF1b. HF diet-fed mice were injected with LV-HNF1b via tail vein. Knockdown of HNF1b was confirmed (Supporting (Supporting Fig. S3C ). HE and Oil Red O staining showed that hepatic lipid contents were increased in LV-shHNF1b-injected HF diet-fed (Fig. 3A) mice. Hepatic TG level in HF diet-fed (Fig. 3B) mice was increased by knockdown of HNF1b. Bodipy and Oil Red O staining showed that knockdown of HNF1b increased lipid accumulation in AML-12 hepatocytes treated by OA or PA (Fig. 3C) . Knockdown of HNF1b worsened both glucose intolerance (Fig. 3D) and insulin resistance (Fig. 3E) , with AUC being significantly increased (Fig. 3D, E, right panel). The data suggest that knockdown of HNF1b worsens fatty liver and glucose intolerance in obese mice.
Knockdown of HNF1b results in fatty liver and impairment of glucose tolerance
To evaluate whether knockdown of HNF1b induces hepatic lipid accumulation, we injected C57BL/6J mice with LV-shHNF1b. Reduced S4A) and fasting blood glucose level, body weight and liver weight were not significantly altered (Supporting Fig. S4B, C, D) . Knockdown of HNF1b resulted in a significant increase in hepatic lipid content in mice, as evidenced by HE and Oil Red O staining (Fig. 4A) mice. Hepatic TG levels were increased by knockdown of HNF1b (Fig. 4B) . Reduced expression of HNF1b induced a significant increase in Bodipy staining in AML-12 hepatocytes, indicating increased lipid accumulation (Fig. 4C) . Knockdown of HNF1b results in significant impairment of glucose tolerance (Fig. 4D ) and insulin sensitivity (Fig. 4E) , with AUC being significantly increased (Fig. 4D, E, right panel) . Insulin-stimulated glucose uptake in AML-12 hepatocytes was markedly reduced by the knockdown of HNF1b (Fig. 4F) . Consistently, reduced expression of HNF1b resulted in decreased insulin-stimulated phosphorylation of Akt in livers of mice ( Fig. 4G ) and AML-12 hepatocytes (Fig. 4H) . Taken together, these data suggest that reduced hepatic expression of HNF1b results in fatty liver, impairment of glucose tolerance and insulin resistance in vivo and in vitro.
3.5. Knockdown of HNF1b worsened HF diet-induced liver injury, resulted in ER stress and increased lipogenesis-related gene expression Knockdown of HNF1b had no significant effect on serum level of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) in mice fed a normal chow diet (Fig. 5A, B) . However, knockdown of HNF1b resulted in a marked increase in ALT and AST concentrations in plasma of mice fed with HF diet (Fig. 5A, B) . Knockdown of HNF1b induced a significant increase in the expression of 78 kDa glucoseregulated protein (GRP78), C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6), and the phosphorylation of eukaryotic initiation factor 2ɑ (eIF2ɑ) (Fig. 5C ), indicating the induction of endoplasmic reticulum (ER) stress. In addition, HNF1b knockdown increased the basal and HF diet-induced expression of fatty acid metabolism-related genes, including peroxisome proliferator-activated receptor ɑ/γ, Srebp-1, FAS, and fatty acid binding protein 4 (FABP4) (Fig. 5D, E, F, G, H) . The protein expression of these genes were also increased by downregulation of HNF1b (Fig. 5I) . These data suggest that reduced expression of HNF1b results worsened HF diet-induced liver injury, induced ER stress and increased fatty acid and TG synthesis-related gene expression.
Upregulation of DPP4 was involved in HNF1b silence-induced hepatic lipid accumulation and metabolic disorder
To further explore the underlying molecular mechanisms of HNF1b downregulation-mediated fatty and metabolic disorder, we performed Affymetrix-based global gene expression analysis on AML-12 cells with HNF1b knockdown. Transcriptome analysis identified 141 more than 1.5-fold differentially expressed genes (DEGs) between LV-Ctrl-AML-12 and LV-shHNF1b-AML-12 cells (Table 1) . Among those DGEs, we focused on dipeptidyl peptidase 4 (DPP4), an important target in the treatment of type 2 diabetes (Table 1) . We validated the altered expression of DPP4 and showed that HNF1b knockdown markedly increased the expression of DPP4 (Fig. 6A, B) . In livers of both genetic and HF diet-induced obese mice, the expression of DPP4 was significantly increased (Fig. 6C, D, E, F) . Upregulation of DPP4 was associated with a significant increase in lipid formation in AML-12 hepatocytes (Fig. 6G and Supporting Fig. S5 ). Silence of DPP4 using shRNAs (Supporting Fig.  S6 ) was associated with HNF1b knockdown-resulted increase of lipid accumulation (Fig. 6H) , decrease of insulin-stimulated glucose uptake (Fig. 6I ) and Akt phosphorylation (Fig. 6J ) in AML-12 hepatocytes. Furthermore, we revealed that the level of DPP4 promoter expression in HNF1b antibody immunoprecipitated mixture was significantly higher than that of IgG, indicating that HNF1b exhibited a direct binding in the promoters of DPP4 (Fig. 6K) . In the presence of PA, the binding of HNF1b in the promoters of DPP4 was significantly reduced (Fig. 6K) , which may contribute to increased expression of DPP4. The results demonstrated that upregulation of DPP4 was involved in HNF1b silence-induced hepatic lipid accumulation and metabolic disorder.
Upregulation of NOX1/superoxide was involved in HNF1b silenceinduced hepatic lipid accumulation and metabolic disorder
In the transcriptome analysis, we also found that nicotinamide adenine dinucleotide phosphate oxidase 1 (NOX1) was increased by HNF1b knockdown (Table 1) . We validated the upregulated expression of NOX1 and showed that HNF1b knockdown increased NOX1 expression (Fig. 7A, B) . In livers of both db/db mice and HF diet-resulted obese mice, the expression of NOX1 was significantly increased (Fig. 7C, D, E, F) . Upregulation of NOX1 (Supporting Fig. S7 ) resulted in a significant increase in lipid formation in AML-12 hepatocytes (Fig. 7G) . Silence of NOX1 (Supporting Fig. S8 ) prohibited the increase of lipid accumulation (Fig. 7H) , decrease of insulin-stimulated glucose uptake (Fig. 7I ) and Akt phosphorylation (Fig. 7J) induced by HNF1b knockdown in AML-12 hepatocytes. Furthermore, we revealed that the level of NOX1 promoter expression in HNF1b antibody immunoprecipitated mixture was significantly higher than that of IgG, indicating that HNF1b exhibited a direct binding in the promoters of NOX1 (Fig. 7K) . In the presence of PA, the binding of HNF1b in the promoters of NOX1 was significantly reduced (Fig. 7K) , which may contribute to increased expression of NOX1. The results demonstrated that upregulation of NOX1 was involved in HNF1b silence-induced hepatic lipid accumulation and metabolic disorder. 
DPP4/NOX1-mediated generation of superoxide was involved in HNF1b silence-induced hepatic lipid accumulation and metabolic disorder
We have previously found that downregulation of HNF1b is associated with oxidative stress. In the current study, we also examined the possible role of redox changes in HNF1b-exhibited regulation of hepatic lipid metabolism. Knockdown of HNF1b increased superoxide level in AML-12 hepatocytes (Fig. 8A) . Silence of both DPP4 and NOX1 inhibited the high level of DHE staining by HNF1b knockdown in AML-12 hepatocytes, indicating that DPP4 and NOX1 were involved in HNF1b knockdown-associated superoxide generation ( Fig. 8B and C) . Moreover, HNF1b knockdown resulted in a significant decrease of glutathione, an important antioxidant protein ( Fig. 8D and E) . Silence of both DPP4 and NOX1 inhibited the reduction of GSH level induced by HNF1b knockdown in AML-12 hepatocytes (Fig. 8D and E) . The results indicated that upregulation of DPP4 and NOX1 was responsible for HNF1b knockdown-induced oxidative stress in AML-12 hepatocytes. Furthermore, we examined the role of superoxide generation in HNF1b knockdown-induced lipid accumulation and insulin resistance. We revealed that treatment with N-acetylcysteine (NAC), a well-known antioxidant, could significantly suppressed HNF1b knockdown-induced ER stress, lipid formation and insulin resistance (Fig. 8F, G and H) . The results indicated that DPP4/NOX1-mediated generation of superoxide was involved in HNF1b silence-induced hepatic lipid accumulation and metabolic disorder. In the next step, we also determined the effect of fatty acids on superoxide level and HNF1b expression. The results showed that PA exposure resulted in a significant increase of DHE staining in AML-12 hepatocytes, which was inhibited by the antioxidant NAC (Fig. 8I) . The expression of HNF1b was markedly decreased by PA, which effect was inhibited by NAC (Fig. 8J) . The results indicated that PA downregulated HNF1b through production of superoxide and this may cause a vicious circle of downregulation of HNF1b and production of superoxide, leading enhancement of ER stress, lipid accumulation and insulin resistance (Fig. 8K ).
Discussion
Although numerous papers have reported the pivotal role of HNF1b inMODY5 and the association between variants of HNF1b and type 2 diabetes, the molecular mechanisms remain unclear. Kornfeld et al. discovered that shRNA-mediated reduction of HNF1b in liver resulted in glucose intolerance, impaired insulin signaling and promoted hepatic gluconeogenesis [22] . In turn, hepatic overexpression of HNF1b improved insulin sensitivity in db/db mice [22] , suggesting an unexpected role for HNF1b in the control of obesity-associated hepatic insulin sensitivity. However, whether abnormal expression of HNF1b is associated with hepatic steatosis has not been established. In this study, we examined the pathophysiological functions and molecular mechanisms of HNF1b in the development of fatty liver and metabolic disorder. We observed that HNF1b expression was decreased in fatty liver under pathological conditions in genetic and diet-induced obese mice and in fasted mice, indicating that reduced HNF1b expression was associated with the development of hepatic steatosis. We also found that knockdown of HNF1b increased hepatic lipid content and induced insulin resistance in mice and in a AML-12 hepatocyte cell line. In addition, knockdown of HNF1b exacerbated HF diet-induced hepatic lipid accumulation, liver injury and insulin resistance in mice and PAinduced lipid accumulation and disturbance of insulin signaling in AML-12 hepatocytes. Moreover, overexpression of HNF1b alleviated HF diet-induced hepatic lipid contents and insulin resistance in mice. These results demonstrated that HNF1b protects against hepatic steatosis and insulin resistance.
PPARγ is the central regulator of fatty acid and lipogenesis through regulating a series of target genes, including Srebp-1, FAS and FABP4 [23, 24] . In contrast, PPARɑ is responsible for fatty acid oxidation and lipolysis. The findings showed that knockdown of HNF1b increased the expression of all these factors. The results indicated that knockdown of HNF1b may induce an increase in both lipogenesis and lipolysis compared to basal condition, and the process of lipogenesis may be predominant. The effect of knockdown of HNF1b on lipolysis needs to be further thoroughly investigated, which may be a consequence of excessive lipid accumulation and could also contribute to insulin resistance. Lipogenesis and ER stress are reciprocally regulated [25] and ER stress is critical for protein homeostasis. However, abnormal ER stress may promote fat accumulation, insulin resistance and inflammation [25] . ER stress is reported to be involved in lipogenesis [26] through proteolytic cleavage of Srebp-1 [27] . ER stress is also involved in the development of insulin resistance. Lipogenesis resulting in lipid droplet accumulation in the ER is known to cause ER stress [28, 29] . Exogenous FABP4 induces ER stress [30] . Activation of PPARα/γ could either promote or inhibit ER stress [31] [32] [33] [34] [35] . We found that downregulation of HNF1b increased lipogenesis-related regulators and activated ER stress. The evidence suggests that enhancement of lipogenesis and ER stress underlie the mechanism by which reduced hepatic expression of HNF1b leads to hepatic steatosis and insulin resistance. To explore the molecular mechanism of HNF1b-exhibited regulation of lipid metabolism and insulin sensitivity, we performed transcriptome analysis and found that DPP4 was significantly increased after the knockdown of HNF1b. DPP4 degrades glucagon-like peptide-1, which stimulates insulin secretion from pancreatic β-cells. DPP4 inhibitors have been introduced for the treatment of type 2 diabetes [36] . Hepatic DPP4 mRNA expression is significantly greater in NAFLD patients than in control subjects and is negatively correlated with homeostatic model assessment (HOMA-IR) and positively correlated with serum cholesterol levels [36] . Inhibition of DPP4 attenuates hepatic steatosis in ob/ob mice [37] and ER stress in db/db mice [38] . We further reported that overexpression of DPP4 increased lipid droplets in AML-12 hepatocytes and downregulation of DPP4 suppressed knockdown of HNF1b-induced TG formation and disturbance of insulin signaling. The promoter region of the DPP4 gene contains functional HNF1 binding sites [38] . Interestingly, HNF1a is a positive transcriptional regulator of DPP4 [38] . Conversely, our results suggest that HNF1b suppresses expression of DPP4. Therefore, it appears that HNF1a and HNF1b differentially regulate the expression of specific gene targets with the ratio of HNF1a and HNF1b likely determining target gene expression levels. Whether there is direct interaction between HNF1a and HNF1b in the regulation of DPP4 expression and the subsequent lipogenesis needs further investigation.
Oxidative stress is a fundamental biological process that promotes the development of fatty liver, obesity and insulin resistance [39, 40] . We also found that knockdown of HNF1b resulted in increase of superoxide level which could be attributed to increased expression of DPP4 and NOX1. The treatment of NAC significantly inhibited HNF1b knockdown-induced ER stress, steatosis, and insulin resistance, suggesting that the production of superoxide played a central role in the adverse effect of HNF1b knockdown. NADPH oxidases are major source of intracellular superoxide [41] . NOX1-mediated production of superoxide is involved in various pathological processes. However, the role of NOX1/superoxide axis in hepatic lipid metabolism and insulin resistance has not been given adequate attention. We reported that hepatic NOX1 expression was increased in genetic and diet-induced obese mice. Overexpression of NOX1 increased lipid droplets in AML-12 hepatocytes and downregulation of NOX1 suppressed knockdown of HNF1b-induced TG formation and impaired of insulin signaling. One possibility is that HNF1b functions as a transcriptional repressor of NOX1, resulting in increase of superoxide generation and subsequent hepatic lipogenesis and insulin resistance. In addition, we found that silence of DPP4 inhibited superoxide generation induced by HNF1b knockdown in AML-12 hepatocytes, indicating that DPP4 also involved in HNF1b knockdown-associated superoxide generation. Previous studies have reported that DPP4 inhibitors played an antioxidant role mainly through regulating expression of antioxidant enzymes and mitochondrial ROS generation [42, 43] . These results indicated that generation of superoxide induced by DPP4 also contributed to the ER tress, hepatic lipid accumulation and insulin resistance. In addition to our findings, there are several literatures reporting the relationship between DPP4 and steatosis. Gemigliptin, an inhibitor of DPP4, improved hepatic steatosis and insulin resistance in HF diet-fed mice, by AMPactivated protein kinase-dependent and c-Jun N-terminal kinase-dependent mechanisms [44] . In addition, DPP-4 inhibition could ameliorate hepatic steatosis and insulin resistance by suppressing hepatic TG and diacylglycerol accumulation through enhanced mitochondrial carbohydrate utilization and hepatic TG secretion/export with a concomitant reduction of uric acid production [45] . In future studies, the mechanism underlying DPP4-induced superoxide generation and whether there exist other mechanisms responsible for DPP4-exhibited hepatic steatosis and insulin resistance in response to HNF1b downregulation are to clarified. We also revealed that PA induced superoxide generation, which was responsible for the downregulation of HNF1b expression. Treatment of NAC significantly restored the expression of HNF1b in PA-treated hepatocytes. The results indicated that fatty acids promotes superoxide generation, decrease HNF1b expression, which could upregulate DPP4 and NOX1, leading to enhancement of superoxide generation and lipid metabolic disorder and forming a vicious circle. Taken together, our current studies demonstrate that HNF1b plays an essential role in controlling hepatic TG homeostasis by regulating DPP4/NOX1/superoxide. In addition to regulating hepatic lipid metabolism, rescue of reduced hepatic HNF1b expression in db/db or HF diet-fed mice improved glucose tolerance and insulin sensitivity. Accordingly, we propose that HNF1b is required to maintain lipid balance in the liver, and its function in lipid metabolism has important implications for the prevention and treatment of NAFLD associated with diabetes and obesity.
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